Bisphosphonate bei malignen Knochentumoren |
| |
Authors: | Prof. Dr. G. Holzer |
| |
Affiliation: | 1. Universit?tsklinik für Orthop?die, Medizinische Universit?t, W?hringer Gürtel 18–20, A-1090, Wien, ?sterreich
|
| |
Abstract: | Bisphosphonates (BPs) are able to prevent, reduce, or delay skeletal complications caused by tumors. Since the introduction of BPs, there has been a marked reduction of skeletal events. Today we can choose from a variety of BPs with different potency, efficacy, dosing, and administration regimens, as well as BPs for different indications. For patients with tumors who have a risk of developing osteoporosis induced by the tumor or antitumor treatment, we should think of prevention. In general, BPs are well tolerated. But there are also side effects: flulike syndrome, arthralgias, or, when administered orally, gastrointestinal symptoms. In a number of cases, the dosing regime must be adjusted according to renal function and baseline creatinine clearance. This paper reviews the current evidence-based use of BPs in solid tumors and the recommendations for treatment. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|